keyword
MENU ▼
Read by QxMD icon Read
search

HSCT

keyword
https://www.readbyqxmd.com/read/28737776/therapeutic-salivary-monitoring-of-iv-busulfan-in-patients-undergoing-hematopoietic-stem-cell-transplantation-a-pilot-study
#1
L M Bezinelli, F P Eduardo, D L C de Carvalho, C E Dos Santos Ferreira, E V de Almeida, L R Sanches, I Esteves, P V Campregher, N Hamerschlak, L Corrêa
Individual therapeutic monitoring of busulfan (BU) minimizes its toxicity and improves the therapeutic outcomes during hematopoietic stem cell transplantation (HSCT). For individual dose adjustment, several blood collections are performed that are uncomfortable for patients. The aim of this pilot study was to validate a laboratory method for quantification of BU in saliva and to present the results obtained using this protocol in HSCT patients. We performed analyses of selectivity, precision and accuracy of saliva with standard concentrations of BU using ultra-high-performance liquid chromatography with diode array detection...
July 24, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28736882/the-clinical-significance-of-monitoring-the-expression-of-the-sil-tal1-fusion-gene-in-t-cell-acute-lymphoblastic-leukemia-after-allogeneic-hematopoietic-stem-cell-transplantation
#2
X Zhao, Y Hong, Y Qin, Y Xu, Y Chang, Y Wang, X Zhang, L Xu, X Huang
INTRODUCTION: SIL-TAL1 rearrangement is common in T-cell acute lymphoblastic leukemia (T-ALL). However, whether this fusion gene might be used as a reliable marker of minimal residual disease (MRD) following allogeneic stem cell transplantation (allo-HSCT) remains unknown METHODS: The clinical data of consecutive 29 patients with T-ALL who received allo-HSCT were collected. Their MRD were evaluated by SIL-TAL1, Wilms' tumor 1 (WT1) expression, and the leukemia-associated immunophenotype (LAIP) ...
July 24, 2017: International Journal of Laboratory Hematology
https://www.readbyqxmd.com/read/28736021/infectious-complications-and-multidrug-resistant-bacteria-in-patients-with-hematopoietic-stem-cell-transplantation-in-the-first-12-months-after-transplant
#3
A César-Arce, P Volkow-Fernández, L M Valero-Saldaña, B Acosta-Maldonado, D Vilar-Compte, P Cornejo-Juárez
BACKGROUND: Hematopoietic stem cell transplantation (HSCT) has been used as treatment in different hematologic and solid malignancies. The aim of this study was to describe the frequency of infectious complications, microbiology, and outcome in patients undergoing HSCT in Mexico during the pre-engraftment period and the impact on mortality rates at 12 months. METHODS: We conducted a retrospective study of all hematologic malignancies that received HSCT from January 2009 and December 2014, at an oncology reference center...
July 2017: Transplantation Proceedings
https://www.readbyqxmd.com/read/28734876/t-cell-depletion-as-an-alternative-approach-for-patients-55-years-undergoing-allogeneic-stem-cell-transplantation-as-curative-therapy-for-hematologic-malignancies
#4
Ann A Jakubowski, Erica Petrlik, Molly Maloy, Patrick Hilden, Esperanza Papadopoulos, James W Young, Farid Boulad, Hugo Castro-Malaspina, Roni Tamari, Parastoo B Dahi, Jenna Goldberg, Guenther Koehne, Miguel-Angel Perales, Craig S Sauter, Richard J O'Reilly, Sergio Giralt
T cell depleted allogeneic hematopoietic stem cell transplantation (TCD HSCT) is curative treatment for hematologic malignancies in adults, shown to reduce graft vs. host disease (GVHD) without increased relapse. We retrospectively reviewed a single center, 11yr experience of 214 patients ≥55yrs to determine tolerability and efficacy in the older adult. The majority (70%) had myeloid diseases and most acute leukemias were in remission. Median age was 61 yrs with related and unrelated donors > 8/10 HLA matched...
July 19, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28733895/clinical-impact-of-pre-transplant-gut-microbial-diversity-on-outcomes-of-allogeneic-hematopoietic-stem-cell-transplantation
#5
Noriko Doki, Masahiro Suyama, Satoshi Sasajima, Junko Ota, Aiko Igarashi, Iyo Mimura, Hidetoshi Morita, Yuki Fujioka, Daisuke Sugiyama, Hiroyoshi Nishikawa, Yutaka Shimazu, Wataru Suda, Kozue Takeshita, Koji Atarashi, Masahira Hattori, Eiichi Sato, Kyoko Watakabe-Inamoto, Kosuke Yoshioka, Yuho Najima, Takeshi Kobayashi, Kazuhiko Kakihana, Naoto Takahashi, Hisashi Sakamaki, Kenya Honda, Kazuteru Ohashi
Post-transplant microbial diversity in the gastrointestinal tract is closely associated with clinical outcomes following allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, little is known about the impact of the fecal microbiota before allo-HSCT. We analyzed fecal samples approximately 2 weeks before conditioning among 107 allo-HSCT recipients between 2013 and 2015. Microbial analysis was performed using 16S rRNA gene sequencing. Operational taxonomic unit-based microbial diversity was estimated by calculating the Shannon index...
July 21, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28733265/-outcomes-of-hematopoietic-stem-cell-transplantation-at-a-limited-resource-center-in-mexico-are-comparable-to-those-in-developed-countries
#6
Eucario Leon Rodriguez, Monica M Rivera Franco
The first hematopoietic stem cell transplantation (HSCT) in Mexico was performed at our Institution in 1980. Eighteen years later our HSCT Program was restructured to reduce transplant related mortality (TRM) and improve overall survival (OS). The aim of this study was to describe outcomes of HSCT at our institution despite limited resources. Consecutive patients undergoing HSCT, from November 1998 to February 2017, were retrospectively analyzed at the National Institute of Medical Sciences and Nutrition Salvador Zubiran in Mexico City...
July 18, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28733131/preclinical-studies-for-a-phase-1-clinical-trial-of-autologous-hematopoietic-stem-cell-gene-therapy-for-sickle-cell-disease
#7
Fabrizia Urbinati, Jennifer Wherley, Sabine Geiger, Beatriz Campo Fernandez, Michael L Kaufman, Aaron Cooper, Zulema Romero, Filippo Marchioni, Lilith Reeves, Elizabeth Read, Barbara Nowicki, Elke Grassman, Shivkumar Viswanathan, Xiaoyan Wang, Roger P Hollis, Donald B Kohn
BACKGROUND AIMS: Gene therapy by autologous hematopoietic stem cell transplantation (HSCT) represents a new approach to treat sickle cell disease (SCD). Optimization of the manufacture, characterization and testing of the transduced hematopoietic stem cell final cell product (FCP), as well as an in depth in vivo toxicology study, are critical for advancing this approach to clinical trials. METHODS: Data are shown to evaluate and establish the feasibility of isolating, transducing with the Lenti/β(AS3)-FB vector and cryopreserving CD34(+) cells from human bone marrow (BM) at clinical scale...
July 18, 2017: Cytotherapy
https://www.readbyqxmd.com/read/28731908/prognostic-factors-in-lung-transplantation-after-hematopoietic-stem-cell-transplantation
#8
Toyofumi F Chen-Yoshikawa, Seiichiro Sugimoto, Takeshi Shiraishi, Masato Minami, Yasushi Matsuda, Masayuki Chida, Sumiko Maeda, Akihiro Aoyama, Yoshinori Okada, Meinoshin Okumura, Akinori Iwasaki, Shinichiro Miyoshi, Takahiro Oto, Hiroshi Date
BACKGROUND: Lung transplantation is the final life-saving option for patients with pulmonary complications after hematopoietic stem cell transplantation (HSCT). Patients undergoing HSCT for hematologic diseases are thought to be high-risk candidates for lung transplantation; therefore, few lung transplants are performed for these patients, and few studies have been reported. This study aimed to describe the characteristics and outcomes of lung transplantation in patients with pulmonary complications after HSCT...
July 21, 2017: Transplantation
https://www.readbyqxmd.com/read/28731588/human-leukocyte-antigen-distribution-and-genomic-ancestry-in-brazilian-patients-with-sickle-cell-disease
#9
M C F da Silva-Malta, P S Rodrigues, L W Zuccherato, F C B de Souza, E M F L Domingues, V R Souza, E Tarazona-Santos, M L Martins
Hematopoietic stem-cell transplantation (HSCT) is currently the only established curative treatment for sickle cell disease (SCD), but is limited by donor availability. Ethnicity is thought to have an impact on the complications experienced by patients that undergo HSCT and on the likelihood of identifying an HLA matched donor. In the present study, we investigated the genomic ancestry and the distribution of HLA allele groups in Brazilian patients with SCD, compared these HLA profiles to worldwide populations and evaluate the availability of HLA-matched donors...
July 21, 2017: HLA
https://www.readbyqxmd.com/read/28729120/hematopoietic-stem-cell-transplantation-for-multiple-myeloma
#10
REVIEW
Heather L Koniarczyk, Christina Ferraro, Teresa Miceli
OBJECTIVE: To provide an overview of the hematopoietic stem cell transplantation (HSCT) process specific to patients with multiple myeloma (MM) and their caregivers. DATA SOURCES: Research studies, book chapters, websites, expert knowledge, and journal articles. CONCLUSION: Although not curative, autologous HSCT is an important, manageable treatment modality, and continues to be a standard of care in MM for those patients who are eligible...
July 17, 2017: Seminars in Oncology Nursing
https://www.readbyqxmd.com/read/28728478/psychosocial-response-to-new-onset-diabetes-as-a-long-term-effect-of-allogeneic-hematopoietic-stem-cell-transplantation
#11
Jill M Olausson, Lauren Clark, Janice M Morse, Marilyn Hammer, Nancy Allen, Marcia Grant
Currently, little information is available to guide health care practitioners on how to facilitate positive outcomes in individuals who develop new-onset diabetes after allogeneic hematopoietic stem cell transplantation (allo HSCT) for treatment of hematological cancers. Results from this constructivist grounded theory study provide a theoretical framework explaining the psychosocial process of change that middle-age and older adults experience when developing new-onset diabetes in this context. Two predominant factors influenced this change: treatment burden and perception of diabetes...
July 1, 2017: Qualitative Health Research
https://www.readbyqxmd.com/read/28728274/-a-retrospective-study-of-10-cases-of-post-transplant-bronchiolitis-obliterans
#12
J J Chai, T Liu, B Q Cai, H D Zhu
Objective: To analyze the clinical features of bronchiolitis obliterans syndrome (BOS) in patients with allogeneic hematopoietic stem cell transplantation (HSCT). Methods: This retrospective study included patients who underwent allogeneic HSCT from January 1998 to December 2016. The clinical features, radiological manifestations and treatment of clinically proven BOS were reviewed. Results: Of 681 patients who experienced HSCT, 10(1.47%) met the diagnostic criteria. The duration of BOS onset after transplantation was 5-48 months, averaging (18±15) months...
July 12, 2017: Chinese Journal of Tuberculosis and Respiratory Diseases
https://www.readbyqxmd.com/read/28724766/a-unique-t-cell-receptor-amino-acid-sequence-selected-by-htlv-i-tax301-309-specific-cytotoxic-t-cells-in-hla-a24-02-asymptomatic-carriers-and-adult-t-cell-leukemia-lymphoma-patients
#13
Yuko Ishihara, Yukie Tanaka, Seiichiro Kobayashi, Koji Kawamura, Hideki Nakasone, Ayumi Gomyo, Jin Hayakawa, Masaharu Tamaki, Yu Akahoshi, Naonori Harada, Machiko Kusuda, Kazuaki Kameda, Tomotaka Ugai, Hidenori Wada, Kana Sakamoto, Miki Sato, Kiriko Terasako-Saito, Misato Kikuchi, Shun-Ichi Kimura, Aki Tanihara, Shinichi Kako, Kaoru Uchimaru, Yoshinobu Kanda
We previously reported that the T-cell receptor (TCR) repertoire of HTLV-I Tax301-309-specific CD8(+) cytotoxic T-cells (Tax-CTLs) was highly restricted and a particular amino acid sequence motif, "PDR", was conserved among HLA-A*24:02(+) ATL patients who have undergone allogeneic hematopoietic cell transplantation (allo-HSCT). Furthermore, we found that donor-derived PDR+CTLs selectively expanded in ATL long-term HSCT survivors with strong CTL activity against HTLV-I. On the other hand, the TCR repertoires in Tax-CTL of asymptomatic HTLV-I carriers (ACs) remain unclear...
July 19, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28721499/treg-protected-donor-lymphocyte-infusions-a-new-tool-to-address-the-graft-versus-leukemia-effect-in-the-absence-of-graft-versus-host-disease-in-patients-relapsed-after-hsct
#14
Mauro Di Ianni, Paola Olioso, Raffaella Giancola, Stella Santarone, Annalisa Natale, Gabriele Papalinetti, Ida Villanova, Stefano Baldoni, Ambra Di Tommaso, Tiziana Bonfini, Patrizia Accorsi, Paolo Di Bartolomeo
In high-risk acute leukemia patients undergoing haploidentical hematopoietic stem cell transplantation (HSCT), adoptive immunotherapy with T regulatory cells (Tregs) and T conventional cells (Tcons) prevented acute and chronic graft-versus-host disease (GvHD), favored post-transplant immunological reconstitution and was associated with a powerful graft-versus-leukemia (GvL) effect. With a particularly innovative approach, we developed a treatment with a Treg-protected donor lymphocyte infusion (DLI) for patients with early relapse after HSCT and we report here the results obtained in the first patient with APL (M3v) relapsed after a second matched allogeneic HSCT (15% blasts and 75% of donor cells in bone marrow)...
July 18, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/28714947/long-term-systolic-function-in-children-and-young-adults-after-hematopoietic-stem-cell-transplant
#15
S J Rotz, C E Dandoy, M D Taylor, S Jodele, J L Jefferies, A Lane, J A El-Bietar, A W Powell, S M Davies, T D Ryan
Congestive heart failure and subclinical left ventricular systolic dysfunction (LVSD) affect long-term survivors of hematopoietic stem cell transplant (HSCT). Echocardiographic measurements of global longitudinal and circumferential strain have shown promise in identifying subclinical LVSD in cancer survivors. We analyzed echocardiograms in 95 children and young adults with malignancies or bone marrow failure syndromes performed before HSCT and 1-6 years after HSCT. We additionally measured the biomarkers soluble suppression of tumorigenicity-2 (sST-2) and cardiac troponin-I (cTn-I) in the same children through 49 days post HSCT...
July 17, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28713390/hematopoietic-stem-cell-transplantation-in-an-infant-with-immunodeficiency-centromeric-instability-and-facial-anomaly-syndrome
#16
Katharina L Gössling, Cyrill Schipp, Ute Fischer, Florian Babor, Gerhard Koch, Friedhelm R Schuster, Jutta Dietzel-Dahmen, Dagmar Wieczorek, Arndt Borkhardt, Roland Meisel, Michaela Kuhlen
Immunodeficiency, centromeric instability, and facial anomaly (ICF) syndrome is a rare autosomal recessive genetic condition with severe immunodeficiency, which leads to lethal infections if not recognized and treated in early childhood. Up-to-date treatment regimens consist of prophylactic and supportive treatment of the recurrent infections. Here, we report the case of a 1-year-old boy of Moroccan consanguineous parents, who was diagnosed at 4 months of age with ICF syndrome with a homozygous missense mutation in the DNMT3B gene...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28712934/donor-lymphocyte-infusions-used-to-treat-mixed-chimeric-and-high-risk-patient-populations-in-the-relapsed-and-non-relapsed-settings-after-allogeneic-transplant-for-hematologic-malignancies-are-associated-with-high-5-year-survival-if-persistent-full-donor-chimerism
#17
Lauren E Caldemeyer, Luke P Akard, John R Edwards, Anand Tandra, Dawn R Wagenknecht, Michael J Dugan
Mixed chimerism (MC), a persistent or increasing number of host cells after allogeneic hematopoietic stem cell transplant (HSCT), is a predictor of disease relapse. Donor lymphocyte infusions (DLI) have the potential to enhance the graft vs. malignancy (GvM) effect, reducing the risk of relapse in patients with MC. Hence, in addition to utilizing DLI in the relapsed setting, there is a motivation to pursue pre-emptive DLI for patients in complete remissions (CR) after HSCT. To assess the safety and efficacy of DLI, records of 86 patients who received DLI between 2003 and 2015 at a single institution were studied retrospectively...
July 13, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28711754/stability-and-priority-of-symptoms-and-symptom-clusters-among-allogeneic-hsct-patients-within-a-5-year-longitudinal-study
#18
Peter Esser, Katharina Kuba, Angela Scherwath, Christoffer Johansen, Anke Schwinn, Lena Schirmer, Frank Schulz-Kindermann, Margitta Kruse, Uwe Koch, Axel Rolf Zander, Nicolaus Kröger, Heide Götze, Anja Mehnert
CONTEXT: Due to toxicity and invasiveness, allogeneic HSCT causes severe and longstanding symptom burden. Longitudinal studies on symptoms and symptom clusters (SC) would be helpful to optimize symptom control, but are rare to date. OBJECTIVES: To investigate stability of symptoms, extract time stable SC and to determine their priority in symptom management. METHODS: In this multicenter study, patients diagnosed with hematological cancer were assessed before conditioning (T0) and three months (T1), one year (T2) and five years (T3) after transplantation...
July 12, 2017: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/28711727/a-chemotherapy-only-regimen-of-busulfan-melphalan-and-fludarabine-and-rabbit-atg-followed-by-allogeneic-t-cell-depleted-hematopoietic-stem-cell-transplants-for-the-treatment-of-myeloid-malignancies
#19
Barbara Spitzer, Ann A Jakubowski, Esperanza B Papadopoulos, Kirsten Fuller, Patrick D Hilden, James W Young, Juliet Barker, Guenther Koehne, Miguel-Angel Perales, Katharine C Hsu, Marcel R M van den Brink, Nancy A Kernan, Susan E Prockop, Andromachi Scaradavou, Hugo Castro-Malaspina, Richard J O'Reilly, Farid Boulad
We sought to develop a myeloablative chemotherapeutic regimen to secure consistent engraftment of T-cell depleted (TCD) hematopoietic stem cell transplants (HSCT) without the need for total body irradiation, thereby reducing toxicity, while maintaining low rates of GvHD and without increasing relapse. We investigated the myeloablative combination of busulfan and melphalan, with the immunosuppressive agents fludarabine and rabbit anti-thymocyte gloubin (r-ATG) as cytoreduction prior to a T-cell depleted HSCT...
July 12, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28710997/dynamics-of-torque-teno-virus-plasma-dnaemia-in-allogeneic-stem-cell-transplant-recipients
#20
Eliseo Albert, Carlos Solano, Tania Pascual, Ignacio Torres, Lisa Macera, Daniele Focosi, Fabrizio Maggi, Estela Giménez, Paula Amat, David Navarro
BACKGROUND: Torque Teno virus (TTV) plasma DNA load directly correlate with the level of immunosuppresion in different clinical settings. It is uncertain whether this may be the case in allogeneic hematopoietic stem cell transplant recipients (allo-HSCT). OBJECTIVES: We characterized the dynamics of TTV DNAemia in patients undergoing T-cell replete allo-SCT. STUDY DESIGN: Retrospective single-center observational study including 72 allo-HSCT patients...
July 8, 2017: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
keyword
keyword
18503
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"